[San Carlos, Calif. – August 16, 2021] – MBC BioLabs is thrilled to announce our latest partner is Eisai Innovation, Inc. (EII), an affiliate of Eisai Co., Ltd. the fully integrated pharmaceutical company based in Tokyo, Japan. Eisai operates through two global business groups, oncology and neurology, which have discovery, clinical, and marketing capabilities. EII serves as a strategic investment arm of Eisai, with the goal of seeking to identify synergies between the scientific community and Eisai’s network of companies.
By partnering with MBC BioLabs, EII becomes a vital member of our open lab ecosystem, enabling us to provide premium, fully equipped and supported lab space to leading early-stage life science companies. Our shared lab and office facilities empower biotech companies to rapidly launch their business while collaborating with other innovators in the field.
We are delighted that EII has joined us in creating a launchpad for breakthrough biotech companies. We welcome EII’s Shun Asami, Senior Director, to MBC BioLabs’ San Francisco office, and look forward to having EII as part of our collaborative community.
About MBC BioLabs
MBC BioLabs is dedicated to helping life-science startups succeed. By renting space as small as a single bench and providing these entrepreneurial scientists with access to millions of dollars of equipment, we allow companies to be fast, focused, and frugal. We now have three sites: one in the Dogpatch neighborhood in San Francisco and two campuses in San Carlos. Each site has a complete molecular biology core facility that allows companies to do experiments on day one, not year one. We have partnerships with leading pharmaceutical and life-science companies as well as a built-in venture capital firm, Mission BioCapital. These partnerships provide our entrepreneurs with valuable insights about where to focus their efforts and accelerates the innovation pipeline. Our labs have truly enabled awesome: since our opening in 2013 we have helped launch and grow 230 companies. These companies have brought 54 programs to the clinic, produced 13 approved diagnostics, and raised over $7 billion!
About Eisai Co., Ltd.
Eisai Co., Ltd. is a leading global pharmaceutical company headquartered in Japan. Eisai’s corporate philosophy is based on the human health care (hhc) concept, which is to give first thought to patients and their families, and to increase the benefits that health care provides to them. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.
Leveraging the experience gained from the development and marketing of a treatment for Alzheimer’s disease, Eisai aims to establish the “Eisai Dementia Platform.” Through this platform, Eisai plans to deliver novel benefits to those living with dementia and their families through constructing a “Dementia Ecosystem,” by collaborating with partners such as medical organizations, diagnostic development companies, research organizations, and bio-ventures in addition to private insurance agencies, finance industries, fitness clubs, automobile makers, retailers, and care facilities. For more information about Eisai Co., Ltd., please visit https://www.eisai.com.